Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer - Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029147

Enrollment

Registered

2017-09-30

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Borderline resectable pancreatic cancer who are planning neoadjuvant chemotherapy with the following criteria 1)no gender 2)age over 20 years old 3)the patients who gained written consent by the patient's free will with sufficient understanding after receiving sufficient explanation for the participation of this study,

Exclusion criteria

Exclusion criteria: Patients judged unsuitable as research subjects

Design outcomes

Primary

Measure	Time frame
R0 resection ratio	—

Countries

Japan

Contacts

Public ContactHiroto Matsui

Yamaguchi University Graduate School of Medicine Department of Gastroenterological, Breast and Endocrine Surgery

matsui-h@yamaguchi-u.ac.jp0836-22-2264

Outcome results